Complete response to second line Paclitaxel every 2 weeks of eyelid kaposi sarcoma: a case report

Ophthalmic Plast Reconstr Surg. 2013 Sep-Oct;29(5):e114-5. doi: 10.1097/IOP.0b013e3182776f32.

Abstract

A 77-year-old male patient presented to our attention with violaceous nodular lesions on the skin of his hands and lower extremities. Clinical and histologic examination supported the diagnosis of Kaposi sarcoma. A first-line systemic chemotherapy based on liposomal doxorubicin at a dosage of 40 mg/m2 every 3 weeks for 5 cycles was carried out, resulting in partial resolution of skin lesions. However, 1 year later, a relapse of the disease in the lower limbs and a new lesion of the left eyelid were found, therefore the patient began a second-line therapy with 100 mg/m2 paclitaxel every 2 weeks. After 8 cycles of therapy, we observed a complete remission of eyelid tumor and a partial response of lower limbs lesions up to 6 months of follow up. In conclusion, eyelid Kaposi sarcoma was successfully treated with paclitaxel every 2 weeks, obtaining a complete response.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents, Phytogenic / therapeutic use*
  • Eyelid Neoplasms / drug therapy*
  • Humans
  • Male
  • Paclitaxel / therapeutic use*
  • Sarcoma, Kaposi / drug therapy*
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Phytogenic
  • Paclitaxel